When will sotoraxibu be available in China?

Sotorasib is the first KRAS G12C inhibitor approved for the treatment of patients with advanced non-small cell lung cancer (NSCLC) harboring KRAS G12C mutations. Although sotorasibu has been approved in the United States, the European Union and other places in 2021, it has not yet been officially launched in mainland China, so patients are currently unable to obtain the drug through formal domestic channels. This KRAS G12C mutation has a high incidence in lung cancer patients, but the options for targeted drug treatment are still limited. As a specific inhibitor of this mutation, sotoracib brings hope to many patients in China who carry this mutation.

Generally speaking, new foreign drugs entering the Chinese market usually need to go through a series of strict clinical trials, drug approval and related document review processes. The clinical trial data collection of sotorasibu in China is nearing completion, and the application for marketing application process may be completed in the next one to two years. Typically, the National Medical Products Administration (NMPA) speeds up or slows down approvals based on trial data and patient demand. If sotoracib can be quickly approved and successfully launched in China, it is expected that domestic patients will be able to obtain the drug through legal channels in the near future.

In addition, China is actively promoting the inclusion of more innovative drugs in the medical insurance catalog. If sotoracib can successfully enter the national medical insurance directory after being launched in China, it will significantly reduce the financial pressure on patients. However, the inclusion of drugs in medical insurance requires medical insurance negotiation. Considering the price and actual demand of drugs, this process may take a long time. Therefore, it is expected that even after sotorasibu is launched in China, it may take some time before it is expected to be included in medical insurance.

Currently, if domestic patients need to use sotoraxib, they usually choose to obtain generic drugs from Laos and other places through overseas channels to meet their treatment needs. In the next one to two years, if sotoracib can be approved and launched in China, it will provide patients with a convenient and compliant drug purchase channel and further improve the accessibility of treatment.